23andMe Holding Co. (ME) Stock Analysis

23andMe Holding Co. (ME) Healthcare & Pipeline Overview

23andMe Holding Co. is a consumer genetics company providing personalized genetic reports and therapeutic development. Through its two segments, Consumer & Research Services and Therapeutics, the company leverages genetic insights for drug discovery and personalized healthcare, operating in the competitive medical diagnostics and research sector.

What Is the Investment Thesis for ME?

23andMe Holding Co. presents a unique investment opportunity within the healthcare sector, driven by its dual focus on consumer genetics and therapeutic development. The company's gross margin of 54.2% indicates strong pricing power in its consumer services. However, the company's negative profit margin of -134.7% raises concerns about profitability. Key growth catalysts include expanding its therapeutic pipeline and leveraging its genetic database for drug discovery. Potential risks include regulatory hurdles and competition in the genetic testing market. Investors should monitor the company's progress in achieving profitability and successfully commercializing its therapeutic assets.

Based on FMP financials and quantitative analysis

ME Key Highlights

Gross Margin of 54.2% indicates strong pricing power in its consumer services segment.

• Market Cap of $15.3M reflects its current valuation in the market.
• Profit Margin of -134.7% highlights ongoing challenges with profitability.
• Collaboration with GlaxoSmithKline provides potential for leveraging genetic insights in drug development.
• Beta of 1.20 suggests higher volatility compared to the overall market.

Who Are ME's Competitors?

ME is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ME's Key Strengths?

Proprietary genetic database

• Established brand recognition
• Strategic partnerships
• Innovative therapeutic pipeline

What Are ME's Weaknesses?

Negative profit margin

• Limited product diversification
• Dependence on regulatory approvals
• High marketing expenses

What Could Drive ME Stock Higher?

Clinical trial results for therapeutic candidates.

• Expansion of genetic testing services.
• Strategic partnerships with pharmaceutical companies.
• Data monetization initiatives.

What Are the Key Risks for ME?

Listing risk — at $0.6063 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.

• Financial-distress signal — its Altman Z-Score of -26.64 sits in the distress zone (elevated bankruptcy risk).
• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Regulatory hurdles for genetic testing and therapeutic products.
• Competition in the genetic testing market.
• Data privacy and security concerns.
• Economic downturn impacting consumer spending.

What Are the Growth Opportunities for ME?

• Expanding Therapeutic Pipeline: 23andMe has the opportunity to leverage its extensive genetic database to identify and develop novel therapies across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases. This expansion can drive revenue growth and enhance the company's long-term value. The market for targeted therapies is projected to reach $150 billion by 2028, presenting a significant opportunity for 23andMe.
• Strategic Partnerships: Collaborating with pharmaceutical companies like GlaxoSmithKline can accelerate the development and commercialization of new drugs. These partnerships provide access to funding, expertise, and distribution channels, enabling 23andMe to expand its reach and impact. The global pharmaceutical market is expected to reach $1.5 trillion by 2026, offering substantial opportunities for strategic alliances.
• Personalized Healthcare Solutions: The company can further develop personalized healthcare solutions based on individual genetic profiles. This includes providing tailored recommendations for diet, exercise, and medication, improving patient outcomes and driving customer loyalty. The personalized medicine market is projected to reach $4.2 billion by 2028, driven by increasing demand for individualized treatment approaches.
• Geographic Expansion: 23andMe can expand its operations into new geographic markets, particularly in Asia and Europe, to reach a broader customer base. This expansion can drive revenue growth and diversify the company's revenue streams. The global genetic testing market is expected to reach $25 billion by 2027, with significant growth potential in emerging markets.
• Data Monetization: 23andMe has the opportunity to monetize its extensive genetic database by providing anonymized data to researchers and pharmaceutical companies for drug discovery and development purposes. This can generate a new revenue stream and contribute to the advancement of medical research. The market for healthcare data analytics is projected to reach $68 billion by 2028, driven by increasing demand for data-driven insights.

What Are ME's Competitive Advantages?

• Proprietary genetic database.
• Established brand recognition in the consumer genetics market.
• Strategic partnerships with pharmaceutical companies.
• Intellectual property related to drug targets.

What Does ME Do?

Founded in 2006 and headquartered in South San Francisco, California, 23andMe Holding Co. has established itself as a prominent player in the consumer genetics and therapeutics industry. The company operates through two primary segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services segment offers a suite of genetic reports to customers, providing insights into their ancestral origins, potential genetic health risks, and carrier status for certain conditions. These reports are generated from saliva samples collected through its proprietary spit kit. The Therapeutics segment focuses on the discovery, development, and commercialization of novel therapies across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases. 23andMe collaborates with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights for drug development. The company's evolution has been marked by expanding its genetic testing services and advancing its therapeutic pipeline, positioning itself at the intersection of personalized healthcare and drug discovery.

What Products and Services Does ME Offer?

• Provides genetic reports on ancestry.
• Offers insights into potential genetic health risks.
• Determines carrier status for certain genetic conditions.
• Develops novel therapies for various diseases.
• Collaborates with pharmaceutical companies for drug discovery.
• Offers out-licensing of intellectual property related to drug targets.

How Does ME Make Money?

• Generates revenue from the sale of genetic testing kits.
• Derives income from providing genetic reports and analysis.
• Focuses on drug development and commercialization.
• Out-licenses intellectual property associated with drug targets.
• Partnerships with pharmaceutical companies for drug development.

What Industry Does ME Operate In?

23andMe Holding Co. operates within the rapidly evolving medical diagnostics and research industry. The market is characterized by increasing demand for personalized medicine and genetic testing services. Key competitors include Danaher Corporation (DHR), IDEXX Laboratories, Inc. (IDXX), Agilent Technologies, Inc. (A), Illumina, Inc. (ILMN), and Guardant Health, Inc. (GH). The company's success depends on its ability to innovate, navigate regulatory challenges, and effectively commercialize its products and services. The industry is also influenced by advancements in genomics and data analytics, driving the development of new diagnostic and therapeutic solutions.

Who Are ME's Key Customers?

• Individuals seeking information about their ancestry.
• People interested in understanding their genetic health risks.
• Researchers and pharmaceutical companies.
• Patients seeking personalized healthcare solutions.

Company Profile

23andMe Holding Co. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Joseph Selsavage. ME has traded publicly since 2020.

23andMe Holding Co.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -26.64 places it in the distress zone, a signal of elevated financial risk.

ME Valuation & Market Position

With a $15.3M market cap, 23andMe Holding Co. sits in the micro-cap segment of the market.

Quarterly Financial Performance: 23andMe Holding Co.

Revenue for 23andMe Holding Co. came in at $25.4M during Jun 2025, a 43.7% contraction versus the preceding quarter. The company recorded a net loss of $23.8M, with diluted EPS of $-0.87. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, ME averaged $-2.26 in diluted EPS.

23andMe Holding Co. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 991.0% below estimates on average.

Wall Street analysts project 23andMe Holding Co. revenue of about $251.4M for fiscal 2027, with EPS near $-7.80.

The most recent 7 insider filings for 23andMe Holding Co. break down as 2 sales and 5 purchases. On net that is roughly 2.4M shares acquired (about $100K) — insiders putting money in tends to read as conviction.

ME Financials

ME Latest News

ME Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources